Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

04/19/2012 | 01:50pm US/Eastern

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

React to this article
Latest news on MERCK & CO., INC.
08/28DJFDA Says Certain Type 2 Diabetes Drugs Can Cause Serious Joint Pain -- Update
08/28DJFDA Says Certain Type 2 Diabetes Drugs Can Cause Serious Joint Pain
08/28DJFDA : Some Diabetes Drugs Can Cause Joint Pain
08/28 ABLYNX : Announces half-year results for 2015
08/27 MERCK : Research Data from Merck & Company Update Understanding of Depression (A..
08/26DJMARKET SNAPSHOT : U.S. Stocks On Track To Snap 6-session Losing Streak
08/26DJMARKET SNAPSHOT : U.S. Stocks Mount Fresh Attempt To Snap Six-session Losing Str..
08/26DJMARKET SNAPSHOT : U.S. Stocks Attempt To Snap Six-session Losing Streak
08/26DJMARKET SNAPSHOT : U.S. Stocks Climb, Try To End Six-session Losing Streak
08/24 AstraZeneca names Genentech's Bohen as chief medical officer
Advertisement
Chart
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
More Financials